	US 11,696,893 B2
	Preparation comprising vonoprazan
Hiroyuki Fujii, Osaka (JP); and Akira Suzuki, Osaka (JP)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Appl. No. 16/629,096
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
PCT Filed Jul. 9, 2018, PCT No. PCT/JP2018/026416 § 371(c)(1), (2) Date Jan. 7, 2020, PCT Pub. No. WO2019/013310, PCT Pub. Date Jan. 17, 2019.
Claims priority of application No. 2017-135046 (JP), filed on Jul. 10, 2017.
Prior Publication US 2020/0163881 A1, May 28, 2020
Int. Cl. A61K 9/14 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 31/4439 (2006.01); A61K 47/12 (2006.01)

CPC A61K 9/14 (2013.01) [A61K 9/0056 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 31/4439 (2013.01); A61K 47/12 (2013.01)]

16 Claims

1. A preparation comprising fine granules or granules comprising

(1) a core granule containing an organic acid salt of vonoprazan,

(2) an intermediate layer containing the same organic acid as the organic acid forming the salt of vonoprazan in (1), or a salt thereof, and

(3) a coating layer containing a water-insoluble polymer,

wherein the organic acid salt of vonoprazan is vonoprazan fumarate, the organic acid or a salt thereof in said (2) is fumaric acid or a salt of fumaric acid.